ASN Update

EPISODE 5

ASN Update: Sparsentan Redefining IgAN Treatment

In this episode of the Rare Kidney Disease Show, a panel of nephrology experts explore the latest data on sparsentan, as presented at ASN Kidney Week 2024.

Dr. Hiddo Heerspink presents a post hoc analysis of the PROTECT trial comprised of patients who achieved complete proteinuria remission.

Dr. Chee Kay Cheung shares interim data from the SPARTAN study on sparsentan therapy in treatment-naïve patients with IgA nephropathy.

Lastly, Dr. Bruce Hendry discusses combination treatment of sparsentan with SGLT2i in the SPARTACUS study.

These discussions are introduced by Dr. Edgar Lerma, who offers his insights into the possible clinical implications of these data.

Also find us on: Apple Podcasts Spotify Vimeo

Watch the video
to see the accompanying
slides and visuals

Episode Summary

“We know that in patients with IgA nephropathy proteinuria is significantly associated with worse kidney outcomes and a reduction in proteinuria has been associated with improved kidney outcomes.” (3:01)

The PROTECT proteinuria remission post hoc analysis showed that more patients treated with sparsentan achieved complete remission of proteinuria (<0.3 g/day) or proteinuria <0.5 g/d than maximum labeled dose irbesartan (2:44)

Complete remission of proteinuria was associated with better preservation of kidney function and numerically less kidney failure events

Interim data from the SPARTAN trial showed that sparsentan treatment in treatment-naïve patients with IgA nephropathy led to rapid and sustained proteinuria reduction of approximately 70% from baseline. In addition to the proteinuria benefits of sparsentan, urinary markers of inflammation were also reduced, suggesting a direct anti-inflammatory effect in people with IgA nephropathy. (7:18)
In the Phase 2 SPARTACUS trial, sparsentan in combination with an SGLT2i was generally well tolerated with no unexpected safety signals (13:09)
Additionally, in SPARTACUS sparsentan resulted in UACR reduction of ≥30% in almost two-thirds of patients and ≥50% in approximately one-third of patients

Disclaimer: Guest speakers of the Rare Kidney Disease Show may be paid consultants of Travere Therapeutics.